Daniel Karlin Sells 5,600 Shares of Mind Medicine (MindMed) (NASDAQ:MNMD) Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) insider Daniel Karlin sold 5,600 shares of Mind Medicine (MindMed) stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the sale, the insider directly owned 425,025 shares in the company, valued at approximately $5,589,078.75. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mind Medicine (MindMed) Trading Down 3.8%

Shares of MNMD opened at $12.95 on Wednesday. The stock’s 50-day moving average price is $12.34 and its 200 day moving average price is $10.51. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -6.35 and a beta of 2.57. Mind Medicine has a 12-month low of $4.70 and a 12-month high of $14.43.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.26). As a group, research analysts predict that Mind Medicine will post -1.35 earnings per share for the current year.

More Mind Medicine (MindMed) News

Here are the key news stories impacting Mind Medicine (MindMed) this week:

• Positive Sentiment: MM‑120 moved into Phase III for GAD and MDD with pivotal readouts expected in 2026 — a clear near‑term clinical catalyst that supports upside expectations for the stock. Read More.
• Positive Sentiment: Broker and analyst enthusiasm (including recent buy/strong‑buy coverage and a handful of high targets) is lifting sentiment and provides potential support for the stock ahead of clinical readouts. Read More.
• Neutral Sentiment: Analyst/ownership mix is mixed: consensus ratings skew positive with an elevated average price target, while institutional ownership (~28%) gives market credibility but also means larger holders could add to volatility. Read More.
• Negative Sentiment: Clustered insider selling on Dec. 26 — CEO Robert Barrow (25,791 shares), Mark Sullivan (11,276 shares) and Daniel Karlin (5,600 shares) — has introduced immediate selling pressure and is the most direct reason cited for the stock trading down today. Read More.
• Negative Sentiment: Fundamental headwinds remain — recent quarterly results missed estimates and analysts model negative EPS for the year, which increases sensitivity to execution and clinical outcomes. Read More.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MNMD shares. Royal Bank Of Canada reduced their price objective on shares of Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Lifesci Capital upgraded shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Tuesday, October 14th. Chardan Capital upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Wednesday, November 19th. Needham & Company LLC set a $28.00 target price on Mind Medicine (MindMed) and gave the stock a “buy” rating in a research report on Monday, October 13th. Finally, Canaccord Genuity Group upped their price target on Mind Medicine (MindMed) from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Mind Medicine (MindMed) has a consensus rating of “Buy” and an average target price of $30.33.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Marshall Wace LLP raised its holdings in shares of Mind Medicine (MindMed) by 31.9% in the second quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock valued at $22,204,000 after buying an additional 828,067 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Mind Medicine (MindMed) by 16.2% in the first quarter. Wellington Management Group LLP now owns 225,928 shares of the company’s stock worth $1,322,000 after acquiring an additional 31,437 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Mind Medicine (MindMed) by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after purchasing an additional 66,663 shares in the last quarter. Ally Bridge Group NY LLC lifted its position in shares of Mind Medicine (MindMed) by 18.1% during the first quarter. Ally Bridge Group NY LLC now owns 390,143 shares of the company’s stock worth $2,282,000 after purchasing an additional 59,868 shares in the last quarter. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Mind Medicine (MindMed) during the second quarter valued at approximately $238,000. Institutional investors own 27.91% of the company’s stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.

The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications.